美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
机构信息
Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT; University of Michigan Comprehensive Cancer Center, University of Michigan Health System, Ann Arbor, MI; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; and American Society of Clinical Oncology, Alexandria, VA.
出版信息
J Oncol Pract. 2010 Jul;6(4):195-7. doi: 10.1200/JOP.777003. Epub 2010 Jun 23.
Abstract
ASCO and CAP collaborated to produce an evidence-based guideline on estrogen and progesterone receptor testing in breast cancer to produce optimal testing performance.
摘要
ASCO 和 CAP 合作制定了基于证据的乳腺癌雌激素和孕激素受体检测指南，以实现最佳的检测性能。
相似文献
1
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
J Oncol Pract. 2010 Jul;6(4):195-7. doi: 10.1200/JOP.777003. Epub 2010 Jun 23.
2
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.乳腺癌中雌激素受体和孕激素受体检测：美国临床肿瘤学会/美国病理学家学院指南更新。
Arch Pathol Lab Med. 2020 May;144(5):545-563. doi: 10.5858/arpa.2019-0904-SA. Epub 2020 Jan 13.
3
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19.
4
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.人表皮生长因子受体 2 检测在乳腺癌中的应用：美国临床肿瘤学会/美国病理学家学会临床实践指南更新。
J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7.
5
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议（未删节版）。
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72. doi: 10.5858/134.7.e48.
6
Pathologists' Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer.病理学家关于乳腺癌雌激素和孕激素受体免疫组化检测的指南建议
Breast Care (Basel). 2010;5(3):185-187. doi: 10.1159/000315039. Epub 2010 Jun 8.
7
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.乳腺癌中雌激素和孕激素受体检测：ASCO/CAP 指南更新。
J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
8
Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.下一代人表皮生长因子受体 2 基因（ERBB2）在浸润性乳腺癌中扩增状态的评估：重点关注 2018 年美国临床肿瘤学会/美国病理学家学院 HER2 检测指南的第 4 组。
Histopathology. 2021 Mar;78(4):498-507. doi: 10.1111/his.14241. Epub 2020 Oct 12.
9
ASCO-CAP guidelines for breast predictive factor testing: an update.美国临床肿瘤学会/美国病理学家学会乳腺癌预测因子检测指南：更新版
Appl Immunohistochem Mol Morphol. 2011 Dec;19(6):499-500. doi: 10.1097/PAI.0b013e31822a8eac.
10
Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.用于选择肺癌患者接受表皮生长因子受体和间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗的分子检测：美国临床肿瘤学会认可美国病理学家学会/国际肺癌研究协会/分子病理学协会指南
J Clin Oncol. 2014 Nov 10;32(32):3673-9. doi: 10.1200/JCO.2014.57.3055. Epub 2014 Oct 13.
引用本文的文献
1
Predicting head and neck cancer response to radiotherapy with a chemokine-based model.利用基于趋化因子的模型预测头颈癌对放疗的反应。
Sci Rep. 2025 Aug 4;15(1):28450. doi: 10.1038/s41598-025-13346-z.
2
Metabolic Imaging Parameters of F FDG PET/CT in Differentiating the Ki-67 Index in Carcinoma Breast.¹⁸F FDG PET/CT代谢成像参数在鉴别乳腺癌Ki-67指数中的应用
Indian J Nucl Med. 2025 Mar-Apr;40(2):67-71. doi: 10.4103/ijnm.ijnm_168_24. Epub 2025 Jun 27.
3
Characterization of Disseminated Tumor Cells (DTCs) in Patients with Triple-Negative Breast Cancer (TNBC).三阴性乳腺癌（TNBC）患者中播散肿瘤细胞（DTCs）的特征分析
Cells. 2025 Jun 6;14(12):857. doi: 10.3390/cells14120857.
4
HER2 and hormone receptor conversion after neoadjuvant therapy for breast cancer.乳腺癌新辅助治疗后的HER2和激素受体转化
Front Oncol. 2025 Jun 9;15:1522460. doi: 10.3389/fonc.2025.1522460. eCollection 2025.
5
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.卡帕替尼联合氟维司群治疗激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者：3期CAPItello-291研究扩展中国队列
Nat Commun. 2025 May 9;16(1):4324. doi: 10.1038/s41467-025-59210-6.
6
Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort.前瞻性瑞典人群队列SCAN-B中雌激素受体低阳性乳腺癌的全球转录复杂性
Clin Cancer Res. 2025 Jul 1;31(13):2695-2709. doi: 10.1158/1078-0432.CCR-24-3435.
7
Discovery of a DNA repair-associated radiosensitivity index for predicting radiotherapy efficacy in breast cancer.发现一种与DNA修复相关的放射敏感性指数用于预测乳腺癌放疗疗效
Front Oncol. 2025 Mar 25;15:1439516. doi: 10.3389/fonc.2025.1439516. eCollection 2025.
8
Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy.聚（ADP-核糖）聚合酶（PARP）抑制剂的作用：乳腺癌治疗的新希望。
Int J Mol Sci. 2025 Mar 19;26(6):2773. doi: 10.3390/ijms26062773.
9
Unveiling Novel miRNA-mRNA Interactions and Their Prognostic Roles in Triple-Negative Breast Cancer: Insights into miR-210, miR-183, miR-21, and miR-181b.揭示新型miRNA-mRNA相互作用及其在三阴性乳腺癌中的预后作用：对miR-210、miR-183、miR-21和miR-181b的见解
Int J Mol Sci. 2025 Feb 23;26(5):1916. doi: 10.3390/ijms26051916.
10
Multi-sequence MRI-based nomogram for prediction of human epidermal growth factor receptor 2 expression in breast cancer.基于多序列磁共振成像的列线图预测乳腺癌中人表皮生长因子受体2的表达
Heliyon. 2025 Feb 1;11(3):e42398. doi: 10.1016/j.heliyon.2025.e42398. eCollection 2025 Feb 15.
本文引用的文献
1
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学院乳腺癌雌激素和孕激素受体免疫组织化学检测指南建议。
Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.5858/134.6.907.
2
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌雌激素和孕激素受体免疫组织化学检测的指南建议。
J Clin Oncol. 2010 Jun 1;28(16):2784-95. doi: 10.1200/JCO.2009.25.6529. Epub 2010 Apr 19.
3
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
Zotero 插件